CADL - Candel Therapeutics: Innovative Cancer Therapies But Short Cash Runway
2024-07-01 18:19:16 ET
Summary
- Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells.
- Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers.
- CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer.
- Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion.
- The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP.
...
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway